Chronic graft-versus-host disease (GVHD) is a cause of late morbidity and mortality after allogeneic stem cell transplant.
Phase 1a of the trial examined dose escalation of IO-202 as a monotherapy and in combination with azacitidine. Phase 1b of ...
At an interim analysis of the phase 3 LITESPARK-011 trial (NCT04586231), the oral combination of belzutifan (Welireg) plus ...
Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns and the need for further research.
An exosome-based treatment of glioblastoma multiforme (GBM) has received orphan drug designation from the FDA. 1 Exousia AI, ...
Somatostatin analogs (SSAs) like octreotide LAR and lanreotide are essential in managing NETs. Standard practice involves ...
A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving ...
CUTNETs aims to improve surgical evidence for NETs by identifying high-risk patients and developing resectability criteria. Collaboration is essential due to the uncommon nature of NETs and the need ...
Rosen's excitement about AI stems from the ability to move beyond population health theories to deliver truly individualized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback